A Phase 3 interventional study of Single-Dose IV Oritavancin Diphosphate and IV Vancomycin in Wound Infection, Abscess and Systemic Inflammation, sponsored by Melinta Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-01.
Sponsored by Melinta Therapeutics, Inc. (part of CorMedix Therapeutics) · Phase 3, Interventional, and Treatment
The purpose of this Phase 3 trial was to evaluate the efficacy, safety, and tolerability of oritavancin in acute bacterial skin and skin structure infections (ABSSSIs), including those caused by methicillin-resistant staphylococcus aureus (MRSA), and to evaluate the potential economic benefit of oritavancin administered as a single 1200-milligram (mg) intravenous (IV) dose.
This was a Phase 3, multicenter, randomized, double-blind, parallel, comparative efficacy and safety study of single-dose IV oritavancin/IV placebo versus IV vancomycin for 7 to 10 days in adults with ABSSSI suspected or proven to be caused by gram-positive pathogens. Approximately 960 participants were to be randomized at 100 centers globally.
In addition, this study characterized the pharmacokinetics (PK) and PK/pharmacodynamics (PD) properties of a single 1200-mg IV dose of oritavancin and evaluated the potential health economic benefits offered by this dosing strategy.
270 studies on the registry are indexed under Wound Infection; 33 are open to participants now.
This study's enrollment of 968 is above the median of 141 across 228 interventional studies indexed under Wound Infection.
Browse Wound Infection studies →Melinta Therapeutics, Inc. is the lead sponsor of 32 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants were included in the study if they met all of the following inclusion criteria:
Exclusion Criteria:
Participants were excluded from the study if any of the following exclusion criteria applied prior to randomization:
Prior systemic or topical antibacterial therapy with activity against suspected or proven gram-positive pathogens within the preceding 14 days unless:
ABSSSI due to or associated with any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Single-Dose IV Oritavancin Diphosphate · Drug: Placebo
Drug: IV Vancomycin
Oritavancin was administered as a single IV dose.
Intravenous vancomycin was administered for a minimum of 7 days and up to a maximum of 10 days.
Intravenous placebo was administered thereafter, for a minimum of 7 days and up to a maximum of 10 days (oritavancin and placebo).
Cessation Of Spread Or Reduction In Size Of Baseline Lesion, Absence Of Fever, And No Rescue Antibiotic Medication At Early Clinical Evaluation (ECE) (48 To 72 Hours)
Clinical response at the ECE visit (48-72 hours following initiation of study drug administration). Early clinical response was defined as a composite outcome based on cessation of spreading or reduction in the size of baseline lesion, absence of fever and no rescue antibiotic medication. A participant was classified as "success" if all of the following were met: cessation of spread or reduction of the lesion (defined as cessation of spread of the redness, edema, and/or induration or reduction in size \[length, width, and area\] of the redness, edema, and/or induration such that the size of the lesion was less than or equal to the size at baseline); resolution (absence) of fever (temperature \<37.7°Celsius at the last 3 consecutive recordings by the same route of administration taken 4 times per day, for example every 6 hours between 48 and 72 hours); no rescue antibiotic medication.
Time frame: 48-72 hours after the initiation of study therapy
Investigator Assessed Clinical Cure Of Treatment With Single-dose IV Oritavancin Compared With IV Vancomycin For 7 To 10 Days At Post-therapy Evaluation (Key Secondary Endpoint)
Compared the clinical efficacy at the post therapy evaluation of oritavancin and vancomycin based on the Investigator examination of the signs and symptoms of the primary acute bacterial skin and skin structure infection (ABSSSI). Investigator assessment of clinical cure was complete or nearly complete resolution of baseline signs and symptoms of the primary infection such that no further treatment with antibiotics was needed.
Time frame: 7-14 days after end of therapy
Number Of Participants With A Lesion Size Reduction ≥20% From Baseline At ECE
Clinical response at the ECE visit (48-72 hours following initiation of study drug administration) based on changes in ABSSSI lesion size measurements from baseline. Participants with a ≥20% reduction in size of baseline lesion were classified a 'success', while those with missing data or those without a reduction in size of baseline lesion ≥20% were classified a 'failure'.
Time frame: 48-72 hours after the initiation of study therapy
| Milestone | Single-Dose 1200 mg Oritavancin | Vancomycin |
|---|---|---|
| Started | 483 | 485 |
| Modified intent to treat population | 475 | 479 |
| Completed | 433 | 423 |
| Not completed | 50 | 62 |
Compared the clinical efficacy at the post therapy evaluation of oritavancin and vancomycin based on the Investigator examination of the signs and symptoms of the primary acute bacterial skin and skin structure infection (ABSSSI). Investigator assessment of clinical cure was complete or nearly complete resolution of baseline signs and symptoms of the primary infection such that no further treatment with antibiotics was needed.
| participants | Single-Dose 1200 mg Oritavancin | Vancomycin |
|---|---|---|
| Clinical Cure | 378 | 383 |
| Clinical Failure | 97 | 96 |
Clinical response at the ECE visit (48-72 hours following initiation of study drug administration). Early clinical response was defined as a composite outcome based on cessation of spreading or reduction in the size of baseline lesion, absence of fever and no rescue antibiotic medication. A participant was classified as "success" if all of the following were met: cessation of spread or reduction of the lesion (defined as cessation of spread of the redness, edema, and/or induration or reduction in size \[length, width, and area\] of the redness, edema, and/or induration such that the size of the lesion was less than or equal to the size at baseline); resolution (absence) of fever (temperature \<37.7°Celsius at the last 3 consecutive recordings by the same route of administration taken 4 times per day, for example every 6 hours between 48 and 72 hours); no rescue antibiotic medication.
| participants | Single-Dose 1200 mg Oritavancin | Vancomycin |
|---|---|---|
| Success | 391 | 378 |
| Failure | 84 | 101 |
Clinical response at the ECE visit (48-72 hours following initiation of study drug administration) based on changes in ABSSSI lesion size measurements from baseline. Participants with a ≥20% reduction in size of baseline lesion were classified a 'success', while those with missing data or those without a reduction in size of baseline lesion ≥20% were classified a 'failure'.
| Participants | Single-Dose 1200 mg Oritavancin | Vancomycin |
|---|---|---|
| Success | 413 | 397 |
| Failure | 62 | 82 |
Collected over Begins from the time the participant provided informed consent through to the last follow-up visit at 60 (+7) days.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single-Dose 1200 mg Oritavancin | 1/473 (0.2%) | 35/473 (7.4%) | 323/473 (68.3%) |
| Vancomycin | 2/481 (0.4%) | 35/481 (7.3%) | 340/481 (70.7%) |
| Event | Single-Dose 1200 mg Oritavancin | Vancomycin |
|---|---|---|
| CellulitisInfections and infestations | 5/473 | 8/481 |
| Skin InfectionInfections and infestations | 3/473 | 1/481 |
| Subcutaneous abscessInfections and infestations | 3/473 | 1/481 |
| Abscess limbInfections and infestations | 3/473 | 0/481 |
| PneumoniaInfections and infestations | 2/473 | 0/481 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 2/473 | 1/481 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 2/473 | 1/481 |
| Skin bacterial infectionInfections and infestations | 0/473 | 2/481 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/473 | 2/481 |
| Deep vein thrombosisVascular disorders | 1/473 | 2/481 |
| Event | Single-Dose 1200 mg Oritavancin | Vancomycin |
|---|---|---|
| NauseaGastrointestinal disorders | 52/473 | 43/481 |
| PruritusSkin and subcutaneous tissue disorders | 16/473 | 44/481 |
| HeadacheNervous system disorders | 34/473 | 38/481 |
| Infusion site reactionGeneral disorders | 19/473 | 34/481 |
| VomitingGastrointestinal disorders | 23/473 | 18/481 |
| DiarrheaGastrointestinal disorders | 23/473 | 17/481 |
| Infusion site extravasationGeneral disorders | 18/473 | 23/481 |
| ConstipationGastrointestinal disorders | 19/473 | 21/481 |
| CellulitisInfections and infestations | 20/473 | 17/481 |
| PyrexiaGeneral disorders | 15/473 | 20/481 |
Modified intent to treat (mITT) population consisting of all participants who were randomized into the trial and received any study drug.
| Age, Continuous(years) | Single-Dose 1200 mg Oritavancin | Vancomycin | Total |
|---|---|---|---|
| Mean | 46.2 ± 14.20 | 44.3 ± 14.50 | 45.2 ± 14.38 |
| Sex: Female, Male(Participants) | Single-Dose 1200 mg Oritavancin | Vancomycin | Total |
|---|---|---|---|
| Female | 174 | 178 | 352 |
| Male | 301 | 301 | 602 |
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.